Y-mAbs Faces Delay In Pediatric Neuroblastoma With Refuse-To-File Letter
Executive Summary
Omburtamab, for CNS metastases resulting from neuroblastoma, needs more clinical and CMC data for its rolling BLA to be reviewed. The company says timelines for lead candidate naxitamab should not be affected.
You may also be interested in...
Roche’s Novel Ranibizumab Implant Among Myriad New Filings In EU
The European Medicines Agency has added 13 new drugs to its list of products that are under review for potential pan-EU marketing approval.
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
12 Approvals To Look Out For In Q4
The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in the coming months, with the help of analysts at Biomedtracker.